PURPOSE: The basal-like phenotype has been found to be an independent poor prognostic factor for breast cancer. The aim of this study was to evaluate the association of WW domain-containing oxidoreductase (WWOX) expression with the basal-like subtype and clinicopathological parameters and to determine the prognostic significance of WWOX expression in patients with breast cancer. METHODS: Immunohistochemical analysis of WWOX expression was performed on 267 breast carcinoma samples, and then the mean value of WWOX expression was correlated to the basal-like status and clinicopathological parameters of the samples. The prognostic value of WWOX in primary breast cancer patients was determined for disease-free survival and overall survival. RESULTS: Expression of WWOX was negative in 29% of cases, and mean WWOX levels were significantly lower in basal-like breast cancers than in those of the non-basal-like subtype (P = 0.01). WWOX negativity was associated with decreased disease-free survival (DFS) (hazard ratio = 1.83; 95% CI, 1.01 to 3.28), but not with overall survival. Other tumor variables that showed a significant association with patient survival times included node status (hazard ratio = 0.38; 95% CI, 0.17 to 0.85) and breast cancer phenotype (hazard ratio = 0.36; 95% CI, 0.19 to 0.68). Multivariate regression analysis showed that lymph node involvement (hazard ratio = 0.43; 95% CI, 0.19 to 0.97) and basal-like subtype (hazard ratio = 0.33; 95% CI, 0.17 to 0.63) were also significant independent prognostic variables, and WWOX expression was of borderline significance for DFS (hazard ratio = 0.56; 95% CI, 0.31 to 1.03). CONCLUSIONS: Reduced WWOX expression is associated with the basal-like subtype and a poor disease-free survival rate for breast cancer patients. Additional studies are warranted to better understand the role of WWOX expression, to further refine prognosis, and to optimize treatment in patients with basal-like breast cancer.
PURPOSE: The basal-like phenotype has been found to be an independent poor prognostic factor for breast cancer. The aim of this study was to evaluate the association of WW domain-containing oxidoreductase (WWOX) expression with the basal-like subtype and clinicopathological parameters and to determine the prognostic significance of WWOX expression in patients with breast cancer. METHODS: Immunohistochemical analysis of WWOX expression was performed on 267 breast carcinoma samples, and then the mean value of WWOX expression was correlated to the basal-like status and clinicopathological parameters of the samples. The prognostic value of WWOX in primary breast cancerpatients was determined for disease-free survival and overall survival. RESULTS: Expression of WWOX was negative in 29% of cases, and mean WWOX levels were significantly lower in basal-like breast cancers than in those of the non-basal-like subtype (P = 0.01). WWOX negativity was associated with decreased disease-free survival (DFS) (hazard ratio = 1.83; 95% CI, 1.01 to 3.28), but not with overall survival. Other tumor variables that showed a significant association with patient survival times included node status (hazard ratio = 0.38; 95% CI, 0.17 to 0.85) and breast cancer phenotype (hazard ratio = 0.36; 95% CI, 0.19 to 0.68). Multivariate regression analysis showed that lymph node involvement (hazard ratio = 0.43; 95% CI, 0.19 to 0.97) and basal-like subtype (hazard ratio = 0.33; 95% CI, 0.17 to 0.63) were also significant independent prognostic variables, and WWOX expression was of borderline significance for DFS (hazard ratio = 0.56; 95% CI, 0.31 to 1.03). CONCLUSIONS: Reduced WWOX expression is associated with the basal-like subtype and a poor disease-free survival rate for breast cancerpatients. Additional studies are warranted to better understand the role of WWOX expression, to further refine prognosis, and to optimize treatment in patients with basal-like breast cancer.
Authors: Chad A Livasy; Gamze Karaca; Rita Nanda; Maria S Tretiakova; Olufunmilayo I Olopade; Dominic T Moore; Charles M Perou Journal: Mod Pathol Date: 2006-02 Impact factor: 7.842
Authors: A J Paige; K J Taylor; C Taylor; S G Hillier; S Farrington; D Scott; D J Porteous; J F Smyth; H Gabra; J E Watson Journal: Proc Natl Acad Sci U S A Date: 2001-09-25 Impact factor: 11.205
Authors: C M Perou; T Sørlie; M B Eisen; M van de Rijn; S S Jeffrey; C A Rees; J R Pollack; D T Ross; H Johnsen; L A Akslen; O Fluge; A Pergamenschikov; C Williams; S X Zhu; P E Lønning; A L Børresen-Dale; P O Brown; D Botstein Journal: Nature Date: 2000-08-17 Impact factor: 49.962
Authors: Sai Yendamuri; Tamotsu Kuroki; Francesco Trapasso; Adam C Henry; Kristoffel R Dumon; Kay Huebner; Noel N Williams; Larry R Kaiser; Carlo M Croce Journal: Cancer Res Date: 2003-02-15 Impact factor: 12.701
Authors: Torsten O Nielsen; Forrest D Hsu; Kristin Jensen; Maggie Cheang; Gamze Karaca; Zhiyuan Hu; Tina Hernandez-Boussard; Chad Livasy; Dave Cowan; Lynn Dressler; Lars A Akslen; Joseph Ragaz; Allen M Gown; C Blake Gilks; Matt van de Rijn; Charles M Perou Journal: Clin Cancer Res Date: 2004-08-15 Impact factor: 12.531
Authors: Tamotsu Kuroki; Sai Yendamuri; Francesco Trapasso; Ayumi Matsuyama; Rami I Aqeilan; Hansjuerg Alder; Shashi Rattan; Rossano Cesari; Maria L Nolli; Noel N Williams; Masaki Mori; Takashi Kanematsu; Carlo M Croce Journal: Clin Cancer Res Date: 2004-04-01 Impact factor: 12.531
Authors: Tamotsu Kuroki; Francesco Trapasso; Takeshi Shiraishi; Hansjuerg Alder; Koshi Mimori; Masaki Mori; Carlo M Croce Journal: Cancer Res Date: 2002-04-15 Impact factor: 12.701
Authors: Martina Kluth; Simon Jung; Omar Habib; Mina Eshagzaiy; Anna Heinl; Nina Amschler; Sawinee Masser; Malte Mader; Frederic Runte; Philipp Barow; Sohall Frogh; Jazan Omari; Christina Möller-Koop; Claudia Hube-Magg; Joachim Weischenfeldt; Jan Korbel; Stefan Steurer; Till Krech; Hartwig Huland; Markus Graefen; Sarah Minner; Guido Sauter; Thorsten Schlomm; Ronald Simon Journal: Oncotarget Date: 2017-11-11